Blood

Article	Citations
Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome	1064
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN	1001
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data	999
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection	974
Platelet gene expression and function in patients with COVID-19	729
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee	593
Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19	586
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	526
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients	471
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial	454
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party	336
Venous thromboembolism in cancer patients: a population-based cohort study	318
Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis	318
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study	300
Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition	283
Outcomes of COVID-19 in patients with CLL: a multicenter international experience	244
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19	242
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia	209
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS	201
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia	196
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma	195
Postdischarge thrombosis and hemorrhage in patients with COVID-19	185
Glucose-6-phosphate dehydrogenase deficiency	180
NPM1-mutated acute myeloid leukemia: from bench to bedside	167
The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice	167

How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies	166
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs	164
Therapeutic options in VEXAS syndrome: insights from a retrospective series	162
Antibody-induced procoagulant platelets in severe COVID-19 infection	159
Postdischarge venous thromboembolism following hospital admission with COVID-19	158
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies	157
Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C	153
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study	152
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells	150
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA	144
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome	143
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma	143
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set	141
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas	140
Management of AL amyloidosis in 2020	139
Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry	136
Prothrombotic immune thrombocytopenia after COVID-19 vaccination	135
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes	130
Novel somatic mutations in UBA1 as a cause of VEXAS syndrome	129
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy	129
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study	126
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial	125
Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2	124
Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study	122
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose	122
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results	121
Developmental trajectory of prehematopoietic stem cell formation from endothelium	121
Diamond-Blackfan anemia	120
Association of clonal hematopoiesis with chronic obstructive pulmonary disease	120
Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset	119
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study	119
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype	118
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis	117
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms	117
Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion	115
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies	115
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells	115
Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation	115
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression	113
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial	113
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma	112
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma	110
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines	109
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells	109
A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma	109
SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein	107
Redefining outcomes in immune TTP: an international working group consensus report	107
Use of convalescent plasma in hospitalized patients with COVID-19: case series	107
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity	106
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis	106

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP	105
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial	102
piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL	102
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy	101
The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD	100
Real-world experience with caplacizumab in the management of acute TTP	100
Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults	100
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study	99
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin	99
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma	99
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated withpiggyBac-modified CD19 CAR T cells	99
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort	99
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study	98
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study	98
Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor	98
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR	98
How I treat relapsed acute lymphoblastic leukemia in the pediatric population	98
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results	98
Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study	97
Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein	97
BCL2 and MCL1 inhibitors for hematologic malignancies	97
HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis	96
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome	95
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis	95
YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner	95
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination	94
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma	94
Cancer immunoediting and immune dysregulation in multiple myeloma	94
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an	93
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma	91
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel	91
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know	91
Cold agglutinin disease revisited: a multinational, observational study of 232 patients	91
COVID-19 coagulopathy, thrombosis, and bleeding	90
Neutrophil extracellular traps promote tPA-induced brain hemorrhage via cGAS in mice with stroke	90
Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CA	89
A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex–mediated DNA replication	88
Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity	87
Platelets and extracellular vesicles and their cross talk with cancer	87
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group	86
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells	86
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma	85
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML	85
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal	85
A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myel	84
Emicizumab for the treatment of acquired hemophilia A	84
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma	83
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals	83
CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity	83
Leukemia secondary to myeloproliferative neoplasms	82
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma	82
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up	82
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies	81
The relationship between ABO blood group, von Willebrand factor, and primary hemostasis	81
Excess heme upregulates heme oxygenase 1 and promotes cardiac ferroptosis in mice with sickle cell disease	81
Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production	81
Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL	81
Comprehensive analyses of B-cell compartments across the human body reveal novel subsets and a gut-resident memory phenotype	80
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia	80
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study	80
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias	79
Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues	79
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL	79
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy	78
Genetics of progression from MDS to secondary leukemia	78
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?	78
Neutrophil extracellular traps promote fibrous vascular occlusions in chronic thrombosis	78
How I treat paroxysmal nocturnal hemoglobinuria	77
Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation	77
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents	77
COVID-19 in patients with hematologic malignancy	76
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial	76
Plasminogen: an enigmatic zymogen	76
Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial	76
Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image data set	75
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults	75
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas	75
Genomic profiling for clinical decision making in lymphoid neoplasms	73
How I treat cold agglutinin disease	73
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia	72

Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)	72
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA	72
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial	72
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL	72
Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment	72
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL	72
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition	71
Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis	71
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial	70
Cytokines and costimulation in acute graft-versus-host disease	70
Single-cell analysis of ploidy and the transcriptome reveals functional and spatial divergency in murine megakaryopoiesis	69
No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation	69
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Trans	69
Vasculopathy in COVID-19	69
Primary central nervous system lymphoma	69
How I treat relapsed or refractory AML	69
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE	69
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL	68
Congenital dyserythropoietic anemias	68
T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis	68
Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers	68
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab	68
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?	68
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib	67
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials	67
Mutational landscape of gray zone lymphoma	67
Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis	67
Lessons to learn from tumor-educated platelets	67
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms	66
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma	66
The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial	66
Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial	66
Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant	66
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR	66
Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients	66
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemi	66
Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency	66
Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with	65
RNF217 regulates iron homeostasis through its E3 ubiquitin ligase activity by modulating ferroportin degradation	65
An intact gut microbiome protects genetically predisposed mice against leukemia	65
Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets	65
A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial	65
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group	64
CD63 is regulated by iron via the IRE-IRP system and is important for ferritin secretion by extracellular vesicles	64
Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition	64
TET2-mutant clonal hematopoiesis and risk of gout	64
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC	63
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma	63
Adult blood stem cell localization reflects the abundance of reported bone marrow niche cell types and their combinations	63
EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity	63
Molecular classification improves risk assessment in adult BCR-ABL1–negative B-ALL	63
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity	63
CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease	63
Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors	62
Germ lineDDX41mutations define a unique subtype of myeloid neoplasms	62
Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project	62
Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies	62
IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice	62
Hemochromatosis classification: update and recommendations by the BIOIRON Society	61
Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN	61
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide	61
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission	61
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials	61
Relationship between clone metrics and clinical outcome in clonal cytopenia	61
Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma	61
Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans	60
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications	60
A comprehensive transcriptome signature of murine hematopoietic stem cell aging	60
Germline TET2 loss of function causes childhood immunodeficiency and lymphoma	60
The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation	60
Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients	60
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria	60
Neutrophil HIF-1α stabilization is augmented by mitochondrial ROS produced via the glycerol 3-phosphate shuttle	59
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia	59
Aspirin and antiplatelet treatments in cancer	59
Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity	59
Platelet MHC class I mediates CD8+ T-cell suppression during sepsis	59
Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs	59
PKM2 promotes neutrophil activation and cerebral thromboinflammation: therapeutic implications for ischemic stroke	59
Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma	58
Very long chain fatty acid metabolism is required in acute myeloid leukemia	58
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes	58
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma	58
Neutrophils in acute inflammation: current concepts and translational implications	58
Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1	58
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy	58
Aging-induced IL27Ra signaling impairs hematopoietic stem cells	57
Acalabrutinib in treatment-naive chronic lymphocytic leukemia	57
Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem/progenitor cells	57
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia	57
Clinical insights into the origins of thrombosis in myeloproliferative neoplasms	57
Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis	57
KSHV/HHV8-mediated hematologic diseases	57
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma	57
Primary vitreoretinal lymphoma: a diagnostic and management challenge	56